Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Every psychiatric disorder has a genetic contribution. Although anxiety and depression are very common diseases, current treatments are not very good. A better understanding of the contribution of genetic variants might help us better diagnose as well as develop new therapies.

Q: Can you tell us about the genetic basis of psychiatric disorders?

JF: Every psychiatric disorder that is studied, to some extent, has a genetic contribution. We know this from twin studies and family studies. The contribution varies according to the disorder: schizophrenia and autism have a relatively high contribution, about 80% of variation is due to variation at a genetic level, whereas the conditions I work on, anxiety and depression, are less genetically determined with heritability of about 40%. To put that into perspective, it's about the same as many other common illnesses, type 2 diabetes would be an example.

Q: Why does your research focus on anxiety and depression?

JF: We work on anxiety and depression because those are the commonest psychiatric conditions. There have been a large number of epidemiological studies across the world and they all come to more or less the same conclusion: that depression has a prevalence of between 9 to 16%, and it varies according to gender. I would expect, on average, that one in 5 to 6 women would have one episode of major depression in their lifetime.

Q: Can your research lead to the development of better therapies?

JF: At the moment we're not very good at treating depression. I'd expect that if I see a patient coming into the clinic, I would have a 50% chance of getting them better within say 2 to 3 years. It's not a very successful approach. We have indications that there are some biological problems, psychology as well, and we know from the genetics that there has to be some genetic predisposition. If we were to understand which genetic variants were contributing to this disorder, the idea is, it might put us on the path to helping our patients better, through the development of new therapies.

Q: What are the most important lines of research that have developed in the past 5 or 10 years?

JF: The most important has been the ability to interrogate entire genomes, to see associations between genetic variance and disease. This has been pioneered for other conditions: asthma, diabetes, hypertension, and recently it has been successful in schizophrenia and autism. These approaches have only just become possible with depression and anxiety, largely because we need well-characterised, very large sample sizes, which are very hard to collect.

Q: Why does your line of research matter, why should we put money into it?

JF: Our research, we hope, will lead to our ability to make better diagnoses, and potentially to develop new therapies for this very common and very disabling condition. If you think of this on a global scale, the impact of depression comes second only to ischaemic heart disease, in terms of its effect on people's lives. That's not to say that the mortality is similar, but the morbidity - the extent to which it affects your ability to get on with your life - is tremendous. It's also relatively underfunded. While cancer and heart disease receive large amounts of money, there is relatively little research funding that goes into depression, and one reason for this is because there have been few leads, few really substantial ways into this. Fortunately this is changing, which is why genetics is important, because it gives us a real lead for the first time.

Q: How does your research fit into Translational Medicine within the Department?

JF: Our research is a paradigm of this. We've moved from working with patients, to very careful phenotypic characterisation, through to the genetic analysis, and once we have that we'll be in a position to understand what the molecular basis is. This will enable us to understand the mechanisms that give rise to the condition, and with that information we will then be able to go back into the clinic and improve care for our patients.

Jonathan Flint

It is now known that genetic variants can form the basis of psychiatric disorders, such as depression and anxiety. Professor Jonathan Flint investigates the genetics behind psychiatric disorders, in particular the origins of stress-related conditions, such as anxiety and depression, for which we have relatively ineffective treatments.

This podcast presents the research done by Professor Flint whilst working in the Nuffield Department of Medicine.

More podcasts related to Ex-faculty podcasts

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Richard Antrobus: Universal Flu Vaccine

A Universal Flu Vaccine would protect against a wide range of strains of the virus. Universal vaccines target the parts of the virus that stay relatively stable and are the same between different strains of flu. The ultimate goal is to produce a vaccine that will eventually replace the normal seasonal flu jab.

Colin Baigent: Lowering cholesterol in chronic kidney disease

The SHARP study involved almost 9,500 volunteers aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Volunteers were randomly allocated to take either cholesterol-lowering therapy with a tablet containing ezetimibe 10mg daily and simvastatin 20mg daily, or matching dummy "placebo" tablets for an average of 5 years.

Colin Baigent: Wider statin use saves lives

Prof Colin Baigent discusses how the benefits outweigh the hazards of Cholesterol-lowering drugs.

Paul Bowness: Spondyloarthritis

Spondyloarthritis describes a group of arthritic illnesses where there is inflammation of the joints of the lower back. Joints become painful and stiff, and inflammation ultimately fuses the spine. A better understanding of the role of various immune components might help us better prevent it and perhaps cure it.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

Hal Drakesmith: Iron and Infection

Pathogens can escape recognition by the immune system, but they require iron from their host to grow and spread. If iron availability is high, infection can progress more rapidly. Diverting iron away from invading microbes slows their growth, giving time for our immune mechanisms to clear the infection. Manipulating iron transport might lead to new strategies to combat infections.

Christian Eggeling: Nano-immunology

Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. This has the potential to help us design new drugs and developing new ways of treating diseases.

Barbara Fielding: Metabolism of Fatty Acids

Obesity puts a huge strain on health care services in the UK, with 61% of people in England being overweight. By tracing fats containing heavy atoms from meals into the blood, her aim is to learn more about fat metabolism and target treatments for the complications associated with obesity and diabetes.

Alexander Finlayson: MedicineAfrica

This podcast presents the research done by Dr Alexander Finlayson whilst working in the Nuffield Department of Medicine. Dr Finlayson now works at the Nuffield Department of Population Health.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.